A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
Active, not recruiting · Phase 3 · NCT04975308
Conditions: Breast Neoplasms, Neoplasm Metastasis
At a glance
- Research payments reported, 2025
- $803,437
- U.S. investigators named
- 21
- Sites paid
- 17
- Planned or actual enrollment
- 874
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Imlunestrant (drug), Exemestane (drug), Fulvestrant (drug), Abemaciclib (drug)
- Dates
- Started 2021-10-04; completion 2027-08
- Results posted
- Yes
The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy, and how well imlunestrant with abemaciclib work compared to imlunestrant in participants with breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have breast cancer that is advanced or has spread to another part of the body. Study participation could last up to 5 years.
From ClinicalTrials.gov, last updated 2026-07-22. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $803,437 in research payments for this study in 2025 (44 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Mikhail I. Shtivelband, MD Hematology & Oncology · Chandler, AZ
- Kristin N. Anderson, MD, MPH Hematology & Oncology · Greenbrae, CA
- Mili Arora, MD Hematology & Oncology · Sacramento, CA
- Ling Ma, MD Hematology & Oncology · Lakewood, CO
- Karen C. Daily Weinstein, D.O. Hematology & Oncology · Gainesville, FL
- Sunil G. Gandhi, MD Medical Oncology · Lecanto, FL
- Amir Harandi, M.D. Medical Oncology · Bradenton, FL
- Santosh M. Nair, MD Hematology & Oncology · Orange City, FL
- Marilyn C. Raymond, M.D. Medical Oncology · West Palm Beach, FL
- Nan Chen Medical Oncology · Chicago, IL
- Peter A. Kaufman, MD Medical Oncology · Lebanon, NH
- Komal Jhaveri Medical Oncology · New York, NY
- Meghna S. Trivedi, MD Medical Oncology · New York, NY
- Jason M. Jones, MD Hematology & Oncology · Cincinnati, OH
- Benjamin L. Cho, M.D. Medical Oncology · Eugene, OR
- Allyson L. Harroff, M.D. Hematology & Oncology · San Antonio, TX
- Kathryn E. Hudson, MD Hematology & Oncology · Austin, TX
- Charles V. Kurkul, M.D. Hematology & Oncology · Denton, TX
- Joyce A. O'shaughnessy, MD Medical Oncology · Dallas, TX
- Paula D. Ryan, MD, PHD Medical Oncology · Shenandoah, TX
- Amanda L. Gillespie-twardy, M.D. Hematology & Oncology · Roanoke, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Memorial Sloan-Kettering $247,816
- US Oncology Research LLC $100,683
- Texas Oncology PA $91,199
- University of Florida $53,816
- Florida Cancer Specialists $52,967
- University of California Davis Medical Center, CA $48,172
- Sarah Cannon Research Institute LLC $42,022
- Oncology and Hematology Assoc of Sw Virginia Inc $34,389
- Marin Endocrine Center $30,949
- Rocky Mountain Cancer Centers LLP $22,737
- Ironwood Cancer and Research Centers $22,042
- Alpha Oncology Research LLC $16,148
- Trustees of Columbia Univ in The City of Ny $15,448
- Univ. of Vermont - Fletcher Allen Health Care, VT $8,896
- University of Chicago $7,390
- Oncology Associates of Oregon PC $4,406
- Avera Mckennan Hospital & University Health Center, SD $4,355
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.